REFRACTORY GLIOMA
Clinical trials for REFRACTORY GLIOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY GLIOMA trials appear
Sign up with your email to follow new studies for REFRACTORY GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with tough cancers: drug targets unique genetic flaw
Disease control OngoingThis study is testing a drug called larotrectinib in children and young adults (ages 1-21) whose advanced solid tumors, lymphomas, or histiocytic disorders have returned or not responded to standard treatments. The drug is given to patients whose tumors have a specific genetic ch…
Matched conditions: REFRACTORY GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Targeted drug trial offers hope for kids with Tough-to-Treat cancers
Disease control OngoingThis study is testing an oral drug called ulixertinib in children and adolescents whose advanced cancers have not responded to standard treatments and have a specific genetic change in a cell pathway called MAPK. The main goal is to see if the drug can shrink tumors and control t…
Matched conditions: REFRACTORY GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New hope for kids with tough cancers: treatment guided by tumor genetics
Disease control OngoingThis study is testing a personalized approach for children and young adults with advanced cancers that have come back or stopped responding to standard treatments. Doctors first test the genetic makeup of a patient's tumor to look for specific changes. If a matching change is fou…
Matched conditions: REFRACTORY GLIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Engineered immune cells injected into brain to fight aggressive cancer
Disease control OngoingThis early-phase study is testing the safety and best dose of a personalized immune cell therapy for adults with recurrent or treatment-resistant malignant brain tumors (glioma). Doctors collect a patient's own immune cells, genetically modify them in a lab to recognize and attac…
Matched conditions: REFRACTORY GLIOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC